Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets

Lake Street Capital Markets analyst Thomas Flaten raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $10.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "Looking ahead five months, the Company will have checked off critical, value-driving milestones, including, most importantly, the submission of the Anaphylm NDA. Preceding this event will be a pre-NDA meeting and pediatric study for Anaphylm and a pre-IND meeting for AQST-108. Assuming success across the board, the Company will enter 2Q25 having submitted an NDA and gained alignment with FDA on the AQST-108 Phase 2 program and continuing to execute on its core partnered business and Libervant. This will not only be validation for
the new course set by CEO Dan Barber following his appointment to the position in mid-2022 but also for investors. We believe the odds of a successful NDA submission and ultimate approval are heavily in favor of the Company, with each step in the process adding further comfort. In our view, Anaphylm has the potential to be a game-changer, not just for patients, caregivers, and physicians,
but also for the Company and its investors."

You May Also Be Interested In

• T1 Energy Inc. (TE) PT Raised to $9 at BTIG
• ON Semiconductor (ON) PT Lowered to $62 at Bernstein SocGen
• Circle Internet Group (CRCL) PT Raised to $87 at TD Cowen